Jordana Bieze Foster

In many ways, the frustration experienced bypatients struggling with mild cognitive impairment(MCI) is matched by the frustration ofclinicians facing the challenge of managing thisheterogeneous condition. The prognosis can bevariable, and no proven therapies exist.

The temporary withdrawal of natalizumab (Tysabri) from the market in February 2005 in response to 3 cases of progressive multifocal leukoencephalopathy (PML) among clinical trial participants was a wake-up call for the neurology community about the risks of therapies for multiple sclerosis (MS). Although natalizumab returned to the market under a restricted distribution program in June 2006, the impact of the withdrawal remains evident in the more guarded optimism now being expressed by clinicians and researchers about the agent and about other immunosuppressive therapies for relapsing- remitting MS (RRMS) in the absence of longterm safety data.

For years experts in multiple sclerosis (MS) have been touting the potential benefits of combination therapies for controlling disease progression. The difficulty in finding just the right combination, however, was evident in the mixed nature of findings presented at the Annual Meeting of the American Academy of Neurology (AAN) in Boston, April 28 to May 5.

On December 8, 1995, Jean-Dominique Baubyshaved, dressed, drank a cup of hot chocolate,and spent the day conducting business as theeditor-in-chief of Elle magazine. By the end ofthat day, 43-year-old Bauby was in a coma,the result of a massive brain stem stroke.

The need for effective management of SCI-related pain may be apparent, but it's far less clear which of a multitude of therapeutic options if any will ultimately provide pain relief in a patient with SCI.

That depression, anxiety, sleep disorders, and other neuropsychological conditions are often associated with chronic pain isn't news to most neurologists. But physicians who do not specialize in pain management are largely unaware of a growing body of research suggesting that the race (a genetic classification) or ethnicity (a cultural classification) of a patient with chronic pain may determine the patient's risk of neuropsychological symptoms.

Focus on Prehospital Stroke Services:

ischemic stroke, statins, lipid-lowering agents, secondary prevention of stroke, stroke prevention

diabetic peripheral neuropathy, neuropathy

spinalcordinjury,locomotortraining

The common conclusion from 2 studies that were conducted in different countries and used different assessment tools is more notable than their differences: preoperative mental health scores are predictive of functional outcomes in patients undergoing total knee replacement (TKR).

Even as data mount in support of rasagiline (Agilect) as an alternative therapy for the motor symptoms of Parkinson disease (PD), additional research on the next generation of dopamine agonists suggests that this class of drugs will not be dispensed with any time soon. Findings presented in April at the annual meeting of the American Academy of Neurology (AAN) linked symptom improvement not only to the monoamine oxidase type B inhibitor but also to several nonergoline agonists, including 2 that target receptors other than D1 and D2 and are delivered transdermally.